Clinical outcomes in an adult patient with mannose phosphate isomerase-congenital disorder of glycosylation who discontinued mannose therapy
Loading...
Date
Authors
Naoman, Kinza
Hendriksz, Christian J.
Radcliffe, Graham
Roncaroli, Federico
Moreea, Sulleman
Hussain, Afifah
Stepien, Karolina M.
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
The mannose phosphate isomerase-congenital disorder of glycosylation (MPI-CDG) is caused by phosphomannose
isomerase deficiency. Clinical features include hyperinsulinaemic hypoglycaemia, protein losing enteropathy,
hepatomegaly and hepatic fibrosis, digestive symptoms and coagulation abnormalities. The condition
is treated with mannose supplementation. Long-term outcomes in adults are not well described. We present a
case of an adult female patient who discontinued mannose therapy in her adolescence. In adulthood she developed
gastrointestinal problems, chronic anaemia and osteophytes in her knees.
Description
Keywords
Adult, Clinical outcomes, Mannose phosphate isomerase-congenital disorder of glycosylation (MPI-CDG), Phosphomannose isomerase deficiency, Coagulation abnormalities, Digestive symptoms, Hyperinsulinaemic hypoglycaemia, Protein losing enteropathy, Hepatomegaly, Hepatic fibrosis
Sustainable Development Goals
Citation
Noman, K., Hendriksz, C.J., Radcliffe, G. et al. 2020, 'Clinical outcomes in an adult patient with mannose phosphate isomerase-congenital disorder of glycosylation who discontinued mannose therapy', Molecular Genetics and Metabolism Reports, vol. 25, pp. 1-4.